LCTX:NYSEAMERICAN
Lineage Cell Therapeutics Inc
$0.95
arrow_upward
+1.61%(+0.015) 1D
Oct 7, 3:03:18 PM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for LCTX...
Open
$0.94
High
$0.96
Low
$0.92
Mkt. cap
240.48M
Avg. vol.
1.35M
Volume
987.91K
52-wk high
$2.09
52-wk low
$0.88
EPS
-$0.14
Beta
1.60
Shares outstanding
252.91M
No. of employees
75
Open
$0.94
High
$0.96
Low
$0.92
Mkt. cap
240.48M
Avg. vol.
1.35M
Volume
987.91K
52-wk high
$2.09
52-wk low
$0.88
EPS
-$0.14
Beta
1.60
Shares outstanding
252.91M
No. of employees
75
News stories
From web sources and news partners
CNBC
·
43 minutes ago
Here comes third-quarter earnings season. Booming profits could propel the S&P 500 to new heights
Yahoo Finance Singapore
·
48 minutes ago
SK Hynix (NasdaqGS:SKHY) Is A Key Memory Partner For AI Chip Growth
WKZO
·
1 hour ago
FireFly Robotics files for Nasdaq direct listing
Quartz
·
5 hours ago
Dow drops 451 points as Treasury yields hit 24-year highs
Profile
Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform, Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Wikipedia
About Lineage Cell Therapeutics Inc